Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad-E6E7 and MG1-E6E7 with Atezolizumab in HPV-Associated Cancers
NCT03618953Phase 1Terminated
- Sponsor
- Turnstone Biologics
- Start
- Jun 2018
- Primary completion
- Mar 2021
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 2
01
Overview
Phase 1, open-label trial of Adenovirus expressing mutant HPV E6/E7 and MG1-E6E7 in HPV-associated cancer (2 arms), sponsored by Turnstone Biologics. Primary endpoints: Safety of Ad/MG1-E6E7 administration at 8 months and Maximum Tolerated Dose / Maximum Feasible Dose. Started Jun 2018; status: terminated.
02
Drugs
Adenovirus expressing mutant HPV E6/E7MG1-E6E7
03
Conditions
HPV-associated cancer
Beyond the preview
Go deeper on NCT03618953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618953.